Neuraxpharm Group has announced it is launching its first products in the United Kingdom.
European specialty pharmaceutical company focused on the treatment of the central nervous system (CNS), Neuraxpharm Group, has announced it is launching its first products in the United Kingdom, in a July 31, 2019 press release.
The company plans to launch differentiated and specialty generics within the UK, which comprises 11% of the European market in terms of CNS pharmaceuticals. In addition to launching products, the company has appointed a general manager (Craig Bowen) to run the UK arm of the business, which will be based in Reading, UK.
“Establishing a strong presence in the UK will enable us to build on our position as a CNS specialist in Europe offering consumer healthcare products, standard generics, and added value medicines,” said Jörg-Thomas Dierks, CEO of Neuraxpharm in the press release. “We are very pleased to welcome Craig to the Neuraxpharm team. His proven track record of launching new pharmaceutical products will be of great advantage in bringing differentiated products to local patients and healthcare professionals in the UK, one of the top five markets in Europe.”
